Can Stage 3 Melanoma Be Cured? Treatment & Prognosis

Many people with stage 3 melanoma are alive and disease-free years after treatment, and a growing number can be considered functionally cured. Five-year melanoma-specific survival across all stage 3 subgroups ranges from roughly 67% to 77% depending on the patient population studied, with the lowest-risk subgroup (stage IIIA) reaching five-year survival rates above 90%.¹ The picture has shifted dramatically in the past decade thanks to immunotherapy and targeted drugs given after surgery, and even more recently by giving those drugs before surgery. “Cure” is a complicated word in oncology, but the honest answer is that a substantial fraction of stage 3 patients will never see their melanoma come back.

What Stage 3 Actually Means

Stage 3 melanoma means the cancer has spread beyond the original skin tumor but has not reached distant organs. Typically that means it has traveled to nearby lymph nodes, or it has produced satellite or in-transit lesions, small deposits of melanoma in the skin or tissue between the primary tumor and the nearest lymph node basin. What it does not mean is that the cancer is in your lungs, liver, brain, or bones. That distinction matters enormously for treatment and outlook.

The current staging system divides stage 3 into four subgroups, IIIA through IIID, based on a combination of the original tumor’s thickness and whether it was ulcerated, the number of lymph nodes involved, whether those nodes were found by a sentinel node biopsy or by a doctor feeling them during an exam, and whether satellite or in-transit deposits are present.² Stage IIIA is the least advanced, often involving a thin, non-ulcerated primary tumor with microscopic disease in just one lymph node. Stage IIID is the most advanced, with a thick, ulcerated primary tumor and heavy nodal involvement. The gap in prognosis between those two ends is wide enough that they are, in practice, very different diseases.

Survival Numbers by Substage

A study reassessing prognosis across three independent stage 3 cohorts found that for stage IIIA patients, five-year melanoma-specific survival was around 80% in a large melanoma registry and as high as 93% in the dataset used to build the current staging system. At ten years those numbers were 71% and 88%, respectively. For stage IIIB the five-year figures were 75% and 83%, and at ten years 61% and 77%.¹ Those ranges reflect real differences in how sick the patients were at diagnosis and how they were treated, but the overall message is that even ten years out, more than half of all stage 3 patients in these cohorts were alive and had not died of melanoma.

For stage IIIC and IIID, the numbers are lower, and those subgroups drive much of the mortality. But even here, survival has improved meaningfully over the past decade. The numbers above come from cohorts that include patients treated before modern adjuvant therapies became standard, so they likely underestimate the outcomes patients diagnosed today can expect.

What “Functional Cure” Means in Melanoma

Oncologists are cautious about the word “cure” because melanoma can recur late, sometimes many years after treatment. But researchers have proposed a working definition of functional cure for advanced melanoma: a patient who has responded to treatment, been off treatment for at least two years, and shows no sign of disease progression. Under this framework, a patient still receiving therapy cannot be considered functionally cured, even if scans are clean.³ This definition was developed primarily in the context of stage 4 melanoma treated with immunotherapy, where survival curves plateau after three to four years. In stage 3, where the cancer has been surgically removed and systemic therapy is given to prevent recurrence rather than to shrink existing tumors, the concept is slightly different but the principle holds: the longer you go without recurrence, the more likely you are to stay disease-free permanently.

Surgery as the Foundation

For most stage 3 melanoma, the starting point is surgery to remove the primary tumor with adequate margins and to address the involved lymph nodes. For years, the standard approach when a sentinel lymph node biopsy came back positive was to go back and remove all the remaining lymph nodes in that basin, a procedure called completion lymph node dissection. That changed after two landmark trials showed it did not improve overall survival.

A large randomized trial of nearly 2,000 patients found that immediate completion dissection did not increase melanoma-specific survival compared with observation and ultrasound monitoring of the node basin. Three-year melanoma-specific survival was about 86% in both groups.⁴ A German trial with longer follow-up confirmed that immediate completion dissection was not superior to observation in terms of distant metastasis-free survival, recurrence-free survival, or overall survival.⁵ Given that completion dissection carries real side effects, including chronic limb swelling, current practice favors a selective approach: observation with close follow-up for patients with low-volume microscopic disease in the sentinel node, and careful individualized discussion for higher-risk patients.⁶

Adjuvant Immunotherapy After Surgery

The biggest leap in stage 3 melanoma outcomes came from drugs given after surgery to mop up any remaining cancer cells that imaging cannot detect. Checkpoint inhibitors, drugs that release the brakes on the immune system so it can recognize and attack melanoma, are now the backbone of this approach.

Pembrolizumab was the first to show a clear benefit in a large randomized trial. Initially, at about 15 months of follow-up, patients receiving pembrolizumab had a one-year recurrence-free survival rate of roughly 75% versus 61% for placebo, cutting the risk of recurrence or death by about 43%.⁷ With seven years of follow-up now available, half of pembrolizumab-treated patients remain recurrence-free at seven years, compared with about 36% on placebo. The benefit held across all substages (IIIA through IIIC), regardless of whether tumors expressed the PD-L1 biomarker, and regardless of whether the tumor carried a BRAF mutation.⁸

Nivolumab, a closely related checkpoint inhibitor, was tested head-to-head against ipilimumab, an older immune drug with more side effects. At 18 months of follow-up the one-year recurrence-free survival rate was about 71% with nivolumab versus 61% with ipilimumab, and nivolumab was better tolerated.⁹ A network analysis comparing multiple adjuvant options confirmed that for patients without a BRAF mutation, both nivolumab and pembrolizumab outperformed ipilimumab in disease-free survival and tolerability.¹⁰

An important finding from the pembrolizumab quality-of-life analysis is that the drug did not have a meaningful long-term impact on health-related quality of life compared with placebo. In other words, the protection against recurrence came without a lasting cost to how patients felt day to day.¹¹

Targeted Therapy for BRAF-Mutant Melanoma

About 40% to 50% of melanomas harbor a mutation in the BRAF gene, and for those patients there is an alternative adjuvant option: the combination of dabrafenib and trametinib, two drugs that directly block the signaling pathway the BRAF mutation drives. In the pivotal trial at roughly three years, the relapse-free survival rate was 58% with the combination versus 39% with placebo.¹² At five years, those numbers settled to 52% versus 36%.¹³

The final analysis with the longest follow-up showed a relapse-free survival benefit that remained stable and a trend toward better overall survival, though the overall survival difference just missed conventional statistical significance in the full population. Among patients specifically with a BRAF V600E mutation (the most common subtype), the overall survival hazard ratio was 0.75, meaning a 25% reduction in the risk of death.¹⁴ For patients with BRAF-mutant melanoma, immunotherapy and targeted therapy produce comparable disease-free survival, so the choice often comes down to side-effect profiles and patient preference.¹⁰

Neoadjuvant Treatment Before Surgery

One of the most exciting recent developments is flipping the sequence: giving immunotherapy before surgery rather than only after it. The logic is that the immune system can mount a stronger response against a tumor that is still in place, generating a broader army of immune cells that can then hunt down any microscopic disease left behind. Multiple phase 2 trials have shown that giving anti-PD-1 therapy alone before surgery produces a major pathologic response in roughly 20% to 30% of patients, and combining two checkpoint inhibitors pushes that rate to 50% to 60%.¹⁵

A randomized trial comparing neoadjuvant-then-adjuvant pembrolizumab against adjuvant-only pembrolizumab found that the neoadjuvant approach significantly improved event-free survival. At two years, 72% of patients in the neoadjuvant group were event-free versus 49% in the adjuvant-only group, and severe side effects were similar between the two arms.¹⁶ This is a meaningful jump and is why neoadjuvant immunotherapy is rapidly becoming the preferred approach for patients with palpable, clinically detectable stage 3 disease.

When and Where Stage 3 Melanoma Recurs

Understanding recurrence patterns matters because it shapes how you will be monitored after treatment. For stage 3 disease, the median time to first recurrence is about 14 months in one study and roughly 1.2 years in another, substantially shorter than for stage 1 or stage 2.¹⁷ Most recurrences happen within the first two to three years, which is why surveillance is most intensive during that window.

Where the melanoma comes back depends on the substage. For stage IIIA, first relapses split fairly evenly between local/in-transit sites, lymph nodes, and distant organs. As the substage increases toward IIIC, the proportion of first relapses showing up as distant metastases climbs: roughly 40% for IIIA, about half for IIIB, and over 60% for IIIC. The lung, liver, and brain are the most common distant sites.¹⁸ This is why higher-substage patients tend to receive more frequent cross-sectional imaging after treatment.

Surveillance After Treatment

Most clinicians favor imaging every three to four months for stage IIIC and IIID patients, particularly during the first two to three years when recurrence risk is highest. For stage IIIA patients the risk of distant spread is lower, and about a third of clinicians use a six-month imaging schedule instead.¹⁹ Beyond imaging, you will have regular skin exams and physical exams of your lymph node basins. The goal is to catch any recurrence early, when it is most treatable.

Circulating tumor DNA, tiny fragments of tumor genetic material that can be detected in a blood draw, is emerging as a promising surveillance tool. In one study of patients receiving neoadjuvant immunotherapy, detectable circulating tumor DNA after surgery was 100% predictive of recurrence, while patients whose circulating tumor DNA disappeared within six weeks of surgery had no recurrences.²⁰ Another study found that detectable circulating tumor DNA during routine surveillance preceded or coincided with clinical recurrence in most cases.²¹ These are small studies, and the technology is not yet standard of care, but it may eventually allow a simple blood test to supplement or even replace some imaging scans.

Why Some Patients Do Not Respond or Relapse

Not everyone benefits equally from immunotherapy or targeted therapy. With BRAF-targeted drugs, about 20% of patients with BRAF-mutant melanoma do not respond at all due to built-in resistance, and among those who do respond, many eventually develop acquired resistance. The tumor finds workarounds: reactivating the same signaling pathway through different mutations, switching to alternative growth-driving pathways, or changing its interaction with the surrounding tissue.²² Researchers have identified specific escape mutations, like a change in MEK2 that reactivates the pathway downstream of where the drugs are blocking it.²³

For immunotherapy, resistance is driven by the tumor learning to hide from the immune system. Tumors can stop displaying the surface signals that immune cells use to identify them, alter their interferon signaling, or activate alternative immune-suppressive pathways that dampen the attack even when the main checkpoint brake is released.²⁴ Understanding resistance is an active area of research and a key reason why combination and sequencing strategies continue to evolve.

Age and Other Special Considerations

Melanoma is common in older adults, and there has been understandable concern about whether aggressive treatment is safe and effective in people over 65 or over 80. The reassuring finding from several studies is that age alone does not appear to be a barrier. One study found that patients older than 65 treated with immunotherapy actually had better progression-free and overall survival than younger patients, and without more immune-related side effects.²⁵ A Dutch registry study of adjuvant immunotherapy in older patients confirmed that the rate of serious side effects was similar in patients aged 65 to 74 and those 75 and older, though patients with multiple other health conditions did face a higher risk of side effects and shorter recurrence-free survival.²⁶ A French study of patients over 80 found that management was generally similar to younger patients and supported treating elderly patients on par with younger ones given the safety and efficacy data.²⁷ The takeaway is that treatment decisions should be guided more by a patient’s overall health and functional status than by their birth certificate.

The Financial Reality

Modern melanoma treatment is expensive. A comparison of patients treated before the immunotherapy era (2007 to 2012) with those treated more recently (2018 to 2019) found that mean healthcare costs for stage 3 melanoma rose from roughly $47,000 to about $67,000, driven largely by systemic therapy costs that jumped from under $10,000 to over $55,000.²⁸ That said, cost-effectiveness analyses have generally concluded that adjuvant pembrolizumab represents reasonable value. One model estimated it added about 3.3 quality-adjusted life years over observation alone, producing an incremental cost-effectiveness ratio of roughly $15,000 per quality-adjusted life year, well below thresholds typically considered acceptable.²⁹ Still, out-of-pocket burden, insurance navigation, and the time costs of frequent treatments and monitoring are real issues that patients should discuss with their care teams early.

Living After Stage 3 Melanoma

Surviving stage 3 melanoma brings its own challenges beyond the physical disease. A cross-sectional study of stage 3 survivors found that while general health status was good by standard quality-of-life measures, disease burden was the main area of impairment. Average distress levels were moderate, and depression and anxiety scores indicated that most patients experienced symptoms only intermittently, but a meaningful minority carried a heavier psychological load.³⁰ Fear of recurrence, scanxiety around surveillance visits, and the lingering effects of treatment (fatigue, joint pain, endocrine side effects from immunotherapy) are part of the landscape for many survivors. Engaging with psycho-oncology support and survivorship programs is not a luxury; it is part of complete care.

In-Transit Metastases and Locoregional Approaches

Some stage 3 patients develop satellite or in-transit metastases, small tumor deposits that appear in the skin or soft tissue between the primary tumor site and the draining lymph nodes. These can be frustrating because they may recur locally even when distant disease is controlled. When surgery is not feasible or deposits keep recurring, options include intralesional therapy, where drugs are injected directly into the tumor. One approach combines an oncolytic virus (T-VEC) with a topical immune stimulant, and has shown promise for achieving local control with minimal side effects, making it a useful option for patients who are not good surgical candidates or who are on immunosuppressive medication for other reasons.³¹

What Is Coming Next

The treatment landscape for stage 3 melanoma continues to move fast. Personalized mRNA-based cancer vaccines are among the most closely watched developments. These vaccines are designed to train a patient’s immune system to recognize unique mutations found only in their individual tumor. Early trial data in melanoma have generated significant interest, and the approach has the advantage of relatively fast production and the ability to trigger both antibody and cellular immune responses.³² The diet-immune axis is another frontier. Based on earlier findings that high dietary fiber intake is linked to better immunotherapy responses, a randomized trial is testing whether a high-fiber dietary intervention during immunotherapy changes the gut microbiome in ways that improve anti-tumor immunity.³³ Neither of these is standard care yet, but they illustrate how rapidly the field is expanding beyond the drugs available today.